Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

May 29-31, 2020 • Virtual   Venetoclax/Obinutuzumab Continues to Demonstrate Superior Efficacy  Long-term results from the CLL14 trial continue to show that fixed-duration venetoclax/obinutuzumab (VenG) continues […]

CLL in Focus

Watch and Wait Remains Best Approach for High-Risk Binet Stage A Chronic Lymphocytic Leukemia The current standard of care for patients with Binet stage A chronic […]

CLL In Focus

Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia Progression-free survival (PFS) is longer in patients with chronic lymphocytic leukemia (CLL) who have a complete […]

Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions

  Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]

Hem/Onc News

Axicabtagene, Second CAR T-Cell Therapy, Approved in Lymphoma The US Food and Drug Administration (FDA) approved the T-cell therapy axicabtagene ciloleucel (Yescarta, Kite) on October 18 […]